Pre-made Certolizumab benchmark antibody ( Fab, anti-TNFA/TNF therapeutic antibody, Anti-DIF/TNFSF2/TNLG1F Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Certolizumab biosimilar, Fab, Anti-TNFA/TNF Antibody: Anti-DIF/TNFSF2/TNLG1F therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Certolizumab pegol, sold under the brand name Cimzia, is a biologic medication for the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) and is manufactured by UCB.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-100-1mg	1mg	3090
GMP-Bios-ab-100-10mg	10mg	Inquiry
GMP-Bios-ab-100-100mg	100mg	Inquiry
GMP-Bios-ab-100-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Certolizumab biosimilar, Fab, Anti-TNFA/TNF Antibody: Anti-DIF/TNFSF2/TNLG1F therapeutic antibody
INN Name	Certolizumab
Target	TNF
Format	Fab
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	5wuv:HL/5wux:HL:AB:CD
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2004
Year Recommended	2004
Companies	UCB
Conditions Approved	Ankylosing spondylitis;Crohn's disease;Plaque psoriasis;Psoriatic arthritis;Rheumatoid arthritis;Spondylitis;Non-radiographic axial spondyloarthritis
Conditions Active	Interstitial cystitis;Juvenile rheumatoid arthritis
Conditions Discontinued	Cognition disorders
Development Tech	na